Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6M03

The crystal structure of COVID-19 main protease in apo form

Summary for 6M03
Entry DOI10.2210/pdb6m03/pdb
Descriptor3C-like proteinase (2 entities in total)
Functional Keywordscoronavirus, covid-19, viral protease, biosynthetic protein
Biological sourceSevere acute respiratory syndrome coronavirus 2 (2019-nCoV)
Total number of polymer chains1
Total formula weight33825.55
Authors
Zhang, B.,Zhao, Y.,Jin, Z.,Liu, X.,Yang, H.,Rao, Z. (deposition date: 2020-02-19, release date: 2020-03-11, Last modification date: 2023-11-29)
Primary citationZhao, Y.,Zhu, Y.,Liu, X.,Jin, Z.,Duan, Y.,Zhang, Q.,Wu, C.,Feng, L.,Du, X.,Zhao, J.,Shao, M.,Zhang, B.,Yang, X.,Wu, L.,Ji, X.,Guddat, L.W.,Yang, K.,Rao, Z.,Yang, H.
Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2.
Proc.Natl.Acad.Sci.USA, 119:e2117142119-e2117142119, 2022
Cited by
PubMed Abstract: The main protease (Mpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a key enzyme, which extensively digests CoV replicase polyproteins essential for viral replication and transcription, making it an attractive target for antiviral drug development. However, the molecular mechanism of how Mpro of SARS-CoV-2 digests replicase polyproteins, releasing the nonstructural proteins (nsps), and its substrate specificity remain largely unknown. Here, we determine the high-resolution structures of SARS-CoV-2 Mpro in its resting state, precleavage state, and postcleavage state, constituting a full cycle of substrate cleavage. The structures show the delicate conformational changes that occur during polyprotein processing. Further, we solve the structures of the SARS-CoV-2 Mpro mutant (H41A) in complex with six native cleavage substrates from replicase polyproteins, and demonstrate that SARS-CoV-2 Mpro can recognize sequences as long as 10 residues but only have special selectivity for four subsites. These structural data provide a basis to develop potent new inhibitors against SARS-CoV-2.
PubMed: 35380892
DOI: 10.1073/pnas.2117142119
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon